Risk factors of thromboembolic disease in adolescent users od COC

Česká verzia

Authors: M. Havlín; D. Ondrová
Authors place of work: Česká společnost gynekologie dětí a dospívajících
Published in the journal: Čes-slov Pediat 2020; 75 (3): 142-145.
Category:

Summary

This article deals with etiopathogenesis of thromboembolic disease and analyzes the main risk mechanisms of its development. In particular, the text emphasizes the multifactoriality of the development of thromboembolic states. It discusses the relationship of thrombophilic mutations to the hormonal treatments and quantifies their risks. Great importance is given to the prevention of thrombophilic stimuli, ie. mainly a rational life style. Despite all the risks, COC is the most reliable contraceptive method (while following the lege artis procedure) and its benefits significantly outweigh the negatives.

Keywords:

adolescent girl – hormonal contraception – risk factors of thromoembolism – prescribing recommendations – thrombophilic mutations

Zdroje

1. Bailly C, Merceron O, Hammoudi N, et al. Cannabis induced acute coronary syndrome in a young female. Int J Cardiol 2010 Aug 6; 143 (1): e4–6.

2. Botzenhardt S, Toni I, Rascher W, Neubert A. Venous thromboembolism in adolescents associated with fourth generation oral contraceptives. Klin Padiatr 2013 Sep; 225 (5): 268–276.

3. Dinger J, Assman A, Mohner S, et al. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health 2010, 36 (3): 123–129.

4. Duchene C, Olindo S, Chausson N, et al. Cannabis-inducedcerebral and myocardial infarction in a young woman. Rev Neurol (Paris) 2010 Apr; 166 (4): 438–442.

5. Dulíček P. Riziko venózního tromboembolismu. Moderní gynekologie, Supplementum B. 2010; 19 (1): 86 – 92

6. Elikowski W, Małek M, Kurosz J, et al. Severe pulmonary embolism in a young marijuana smoker. Kardiol Pol 2011; 69 (11): 1168–70

7. Hadačová I. Trombóza a hormonální antikoncepce u mladistvých dívek. Pediatr praxi 2012; 13(4): 225–226

8. Havlín M. Antikoncepce mladistvých. In: Hořejší J, a kol.: Dětská gynekologie. Praha: Mladá fronta, 2017.

9. Křepelka P. Hormonální antikoncepce a kardiovaskulární systém. Postgrad Med 2012; 3: 255–260.

10. Kessler P. Trombofilní stavy. Interní Med 2006; 9: 374–379.

11. Kvasnička J. Doporučený postup pro indikaci molekulárně genetických vyšetření v rámci diagnostiky trombofilních stavů v žilním systému. Vnitř Lék 2010; 56 (12): 1251.

12. Lidegaard O. Hormonal contraception and risk of venous thromboembo-lism: national follow-up study. BMJ 2009 Aug 13, p. 339.

13. Martínez F, Avecilla A. Combined hormonal contraception and venous thromboembolism. Eur J Contracept Reprod Health Care 2007 Jun; 12 (2): 97–106.

14. Rott H. Contraception, venous thrombosis and biological plausability. Minerva Med 2013 Apr; 104 (2): 161–167.

15. Pillai P, Bonny AE, O‘Brien SH. Contraception-related venous thromboembolism in a pediatric institution. J Pediatr Adolesc Gynecol 2013 Jun; 26 (3): 186–188.

16. Rott H. Hormonal contraception in thrombophilic adolescents: risk of thrombosis and recommendations. Hamostaseologie 2012; 32 (1): 15–21.

17. Roztočil A. Moderní gynekologie. Praha: Grada Publishing, 2011.

18. Schramm G, Schrah B. The efficacy and safety of an oral contraceptive containing chlormadiononacetate: reset of pooled analysis of non interventional trials in adult and adolescent women. Contraception 2011; 84: 390–401.

19. Sidney S, Cheetham TC, Connell FA, et al. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascul arevents in new users. Contraception 2013 Jan; 87 (1): 93–100.

20. Sultan C. Pediatric and Adolescent Gynecology. Basel: Karger, 2012.

21. Unzeitig V, Čepický P, Dvořák V, et al. Doporučení k předpisu kombinované hormonální antikoncepce. Čes Gynekol 2012; 77 (6): 597–599.

22. van Vlijmen EF, Veeger NJ, Middeldorp S, et al. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or protrombin mutation: a rational approach to contraception. Blood 2011 Aug 25; 118 (8): 2055–2061.

23. Verhaeghe J. Clinical practice: Contraception in adolescents. Eur J Pediatr 2012 Jun; 171 (6): 895–899.